查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425115

動物生物技術市場 - 2024 年至 2029 年預測

Animal biotechnology Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

動物生物技術市場預計在預測期內複合年成長率為 6.28%。

動物生物技術已經生產出具有更高生長速度、抗病能力以及合成治療性蛋白質的能力的動物。隨著動物基因組定序、基因表現和動物細胞代謝譜的最新進展，動物生物技術也取得了進展。基因組編輯技術（包括 TALENS、CRISPR-Cas 和鋅指核酸酶）的最新進展，為快速改變動物的遺傳組成提供了新的可能性，從而改善動物的健康和福利、農業生產力和抗病能力。

動物生物技術市場促進因素

對基因工程治療性蛋白質的需求不斷成長，以提高抗病能力、在癌症治療中的應用以及增加動物的預防保健，是動物生物技術市場的一些主要成長要素。對農業、肉類生產和動物源性產品中使用動物的需求不斷增加，社會對動物健康和福利的關注不斷增加，動物在人類藥物生產中的作用不斷擴大，以及畜牧業的增加，所有這些因素都促成了擴張生物技術市場。

狗的肥胖、發炎和癌症盛行率增加

狗最常見的營養問題是肥胖，而最近的肥胖流行是動物生物技術市場擴張的主要驅動力。在一些國家，肥胖在狗中很常見。慢性惡性度發炎是肥胖對健康產生許多負面影響的常見解釋。這已被普遍認可和接受，多項研究表明肥胖與多種惡性及相關影響的風險增加之間存在關聯。這些解釋極為重要，因為與肥胖一樣，近年來狗的癌症發生率增加，並且是這些動物死亡的重要原因。

政府加大力度

根據「同一個健康」方針，為了提高印度對潛在動物流行病的準備和應對能力，印度漁業、畜牧業和酪農部長帕肖坦·魯帕拉(Shri Parshottam Rupala) 宣布，動物流行病防範計劃和世界銀行宣布動物衛生系統支持資助一個健康。該計劃的重點是對動物和人類都危險的通用感染疾病，旨在提高印度對動物流行病的準備和應對能力。該計劃將透過社區參與增加農民的知識，同時改善獸醫服務和基礎設施、疾病監測能力、早期發現和應對以及動物衛生專業人員的能力。此外，2021年1月，加拿大政府和安大略省政府將透過加拿大農業合作夥伴關係提供高達400萬加元的資金，以確保農民在需要時能夠獲得獸醫服務。

疫苗需求增加

動物生物技術市場疫苗成長的主要原因是動物疾病盛行率上升。這些疾病透過攝取受污染的食物或水、透過與病人或動物的密切接觸或透過其他自然方式從動物自然傳播給人類。此外，將於 2023 年 6 月推出 NANDI（新藥和新免疫系統核准），這表明 DAHD 在實施動物流行病防範計劃 (APPI) 中指示的治療方法方面正在取得進展。此外，2023年7月，支持獸用疫苗的使用和開發的疫苗評估和抗菌替代品中心（CVEAA）在堪薩斯州立大學獸醫學院正式成立。

在北美，動物生物技術市場預計將穩定成長。

醫療保健計劃的存在和對動物健康促進的持續努力預計將增加該地區動物生物技術市場的成長潛力。此外，該地區強勁的研發投資預計將加速北美動物生物技術市場的擴張。例如，2023年5月，美國國家標準與技術研究院（NIST）和美國食品藥物管理局，透過使用基因組編輯改變動物基因組來開發新型動物生物技術產品的研究人員和公司將共同宣布旨在提供重要新資源的計劃。 FDA 正在致力於這項舉措，作為我們不斷努力推進安全有用的生物技術產品開發的一部分。

CVM中的動物生物技術產品

CVM 致力於利用科學和基於風險的法律規範來推進新技術，生產安全可靠的產品，同時保持客戶信任。動物中的 IGA 和 ACTP 是 CVM 促進和支持其開發的新型動物用藥品的兩個例子。獸醫創新計劃 (VIP) 使監管流程更加清晰，加速研究和開發，並支持以有效且可預測的方式獲得獸醫 ACTP 和 IGA核准，以開發新動物用藥品。由 CVM 設立，旨在促進

主要政府計劃

  • 一個健康舉措：獸醫、醫學、農業、環境、林業、氣象和其他學科之間的通用，以識別、預防和控制人畜共患和跨境動物疾病。為了促進跨部門合作，該部建立了海得拉巴國家衛生與人類服務研究所(NIAB) 的「同一個健康中心」。
  • 獸醫生物生物製藥轉化研究平台 (TRPVB) 是生物製藥。-清奈已建立了名為TRPVB 的合作夥伴關係。 TRPVB 的目標是在現場提供獸醫疫苗、診斷和其他生物製藥，並利用其優勢來改善農業用地的經濟狀況並提高動物健康和產量。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章動物生物技術市場：依產品

  • 介紹
  • 診斷測試
  • 疫苗
  • 藥物
  • 繁殖和遺傳
  • 飼料添加劑

第6章動物生物技術市場：依應用分類

  • 介紹
  • 動物疾病診斷
  • 動物疾病治療
  • 預防保健
  • 藥物開發
  • 其他

第7章動物生物技術市場：依最終用途分類

  • 介紹
  • 實驗室
  • 內部檢查
  • 診所
  • 其他

第8章動物生物技術市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第10章 公司簡介

  • Zeus Biotech Pvt. Ltd.
  • Invetx
  • Ingenta Connect
  • Kingfisher Biotech
  • Animab
  • Boehringer Ingelheim
  • Beveridge & Diamond PC
  • RSPCA
  • Santa Cruz Biotechnology
  • Pfizer
簡介目錄
Product Code: KSI061616206

The animal biotechnology market is estimated to grow at a CAGR of 6.28% during the forecast period.

Animals with enhanced growth rates, illness resistance, or the ability to synthesise therapeutic proteins have all been created via animal biotechnology. Animal biotechnology has advanced owing to recent advances in the sequencing of animal genomes, gene expression, and metabolic profiling of animal cells. Recent advancements in genome editing technologies, including TALENS, CRISPR-Cas, and Zinc Finger Nucleases, have opened up new possibilities for rapidly changing an animal's genetic composition to improve its health and well-being, agricultural productivity, and disease resistance.

Driving factors for the animal biotechnology market

The growing demand for genetically engineered therapeutic proteins that offer improved disease resistance, their use in the treatment of cancer, and increased preventative care for animals are a few key growth drivers for the animal biotechnology market. Rising demand for the use of animals in agriculture, meat production, and animal-based products, rising public concern for the health and welfare of animals, an expanding role for animals in the creation of human pharmaceuticals, and an increase in animal adoption are all factors that contribute to the animal biotechnology market expansion.

Increasing prevalence of obesity, inflammation and cancer in dogs

The most prevalent nutritional problem in canines is obesity, and it has become more widespread in recent years which is a major driving factor for the animal biotechnology market expansion. Obesity is prevalent in dogs in several nations. Chronic low-grade inflammation is a common explanation for why obesity has so many detrimental effects on one's health. This is generally recognised and acknowledged, and multiple research shows a link between obesity and an increased risk of developing some malignancies and associated effects. These explanations are crucial since, like obesity, dog cancer incidence has grown recently, making it a substantial cause of death for these animals.

Increasing government initiatives

To improve India's preparedness and response to potential animal pandemics in line with the One Health approach, Union Minister for Fisheries, Animal Husbandry, and Dairy, Shri Parshottam Rupala, unveiled the Animal Pandemic Preparedness Initiative and the World Bank-funded Animal Health System Support for One Health. With an emphasis on zoonotic illnesses that are dangerous to both animal and human health, this effort seeks to improve India's readiness for and response to animal pandemics. Through community engagement, this effort works to increase farmer knowledge while also enhancing veterinarian services and infrastructure, disease surveillance capabilities, early detection and response, and the ability of animal health experts. Additionally, in January 2021, through the Canadian Agricultural Partnership, the governments of Canada and Ontario are funding up to $4 million to increase farmers' access to veterinary services when they need them.

Increasing demand for vaccines

The rising prevalence of animal illnesses is the major reason for the growth of vaccines in the animal biotechnology market. Close contact with diseased people or animals, or other natural means, these illnesses are naturally passed from animals to humans because of contaminated food and water intake. Furthermore, in June 2023, the introduction of NANDI (NOC Approval for New Drug and Inoculation System) showed that DAHD is making progress towards implementing the treatments outlined in its Animal Pandemic Preparedness Initiative (APPI). Furthermore, in July 2023, the Centre on Vaccine Evaluation and Alternatives for Antimicrobials, or CVEAA, officially opened at Kansas State University's College of Veterinary Medicine to assist the use and development of animal vaccines.

In North America, it is projected that the animal biotechnology market will grow steadily.

It is projected that the existence of healthcare programmes and a rise in the number of efforts to enhance animal health will increase this region's potential for animal biotechnology market growth. Additionally, it is projected that the region's strong R&D investment would accelerate animal biotechnology market expansion in North America. For instance, in May 2023, the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration jointly announced a project that aims to provide an important new resource for researchers and businesses developing novel animal biotechnology products by using genome editing to change the animals' genomes. The FDA is working on this initiative as part of its ongoing efforts to promote the development of safe, useful biotechnology products.

Animal Biotechnology Products at CVM

CVM is dedicated to advancing new technologies for the production of safe and reliable goods while preserving customer confidence via the use of a science- and risk-based regulatory framework. IGAs in animals and ACTPs are the two examples of novel animal products that CVM promotes and supports in their development. The Veterinary Innovation Programme (VIP), which offers more clarity in the regulatory process, promotes research and development, and supports an effective and predictable pathway to approval for ACTPs and IGAs in animals, was established by CVM to facilitate advancements in the development of novel animal products.

Major Government Programs

  • One Health Initiative, the Department established a "One Health Centre" at the National Institute of Animal Biotechnology (NIAB), Hyderabad to foster cross-sectoral cooperation between the veterinary, medical, agricultural, environmental, forestry, meteorological, and other fields to identify, prevent, and control zoonoses and transboundary animal diseases.
  • Translational Research Platform for Veterinary Biologicals (TRPVB), to allow a collaborative and coordinated approach for the translation of innovations in the domain of veterinary biologicals, vaccines, and diagnostics, the Department of Biotechnology (DBT) and TANUVAS-Chennai have formed a partnership known as TRPVB. The goal of TRPVB is to translate veterinary vaccinations, diagnostics, and other biologicals into use in the field and to use their benefits to raise farmland's economic standing and increase animal health and production.

Market Key Developments

  • In June 2023, according to IDEXX Laboratories, Inc., a world leader in pet healthcare innovation the first veterinary diagnostic test for identifying kidney damage in cats and dogs was released.
  • In May 2023, Evonik introduced a new generation of Biolys®, a tried-and-true source of lysine for animal feeds. This is in keeping with the company's legacy of providing the market with cutting-edge goods and services to benefit its clients.
  • In May 2022, Animal health industry pioneer Boehringer Ingelheim announced the release of TwistPak®, a unique mixing platform. It enables swine farmers to swiftly, conveniently, and flexibly mix two vaccinations, Ingelvac CircoFLEX® and Ingelvac MycoFLEX®. TwistPak® will be offered worldwide in all certified presentation sizes.

Segmentation:

By Product

  • Diagnostic Tests
  • Vaccines
  • Drugs
  • Reproductive and Genetic Medications
  • Feed Additives

By Application

  • Diagnosis of Animal Disease
  • Treatment of Animal Disease
  • Preventive Care of Animals
  • Drug Development
  • Others

By End Use

  • Laboratories
  • In-house Testing
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ANIMAL BIOTECHNOLOGY MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Diagnostic Tests
  • 5.3. Vaccines
  • 5.4. Drugs
  • 5.5. Reproductive and Genetic
  • 5.6. Feed Additives

6. ANIMAL BIOTECHNOLOGY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diagnosis of Animal Disease
  • 6.3. Treatment of Animal Disease
  • 6.4. Preventive Care of Animals
  • 6.5. Drug Development
  • 6.6. Others

7. ANIMAL BIOTECHNOLOGY MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Laboratories
  • 7.3. In-house Testing
  • 7.4. Clinics
  • 7.5. Others

8. ANIMAL BIOTECHNOLOGY MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Zeus Biotech Pvt. Ltd.
  • 10.2. Invetx
  • 10.3. Ingenta Connect
  • 10.4. Kingfisher Biotech
  • 10.5. Animab
  • 10.6. Boehringer Ingelheim
  • 10.7. Beveridge & Diamond PC
  • 10.8. RSPCA
  • 10.9. Santa Cruz Biotechnology
  • 10.10. Pfizer